|
Arribas F; SEC Working Group for the 2016 ESC Guidelines for the Management of Atrial Fibrillation:, Arribas F, Roldán I, Luis Merino J, Roldán V, Arenal Ÿ, Tamargo J, Ruiz-Granell R, Mont L, Anguita M, Marín F; Reviewers for the 2016 ESC Guidelines for the Management of Atrial Fibrillation:, Barrios Alonso V, Barón G, Esquivias, Cosín Sales J, Díaz Infante E, Escobar Cervantes C, Ferreiro Gutiérrez JL, Guerra Ramos JM, Jiménez Candil FJ, Pérez Castellano N, Sambola Ayala A, Tello Montoliu A; SEC Guidelines Committee:, San Román A, Alfonso F, Arribas F, Evangelista A, Ferreira I, Jiménez M, Marín F, de Isla LP, Rodríguez Padial L, Sánchez PL, Sionis A, Vázquez R. Comments on the 2016 ESC Guidelines for the Management of Atrial Fibrillation. Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):2-8. doi: 10.1016/j.rec.2016.11.032. English, Spanish. PubMed PMID: 28038728.
AÑO: 2017; IF: 5.166
|
28038728
|
García-Fernández A, Roldán V, Rivera-Caravaca JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY, Marín F. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep. 2017 Jan 30;7:41565. doi: 10.1038/srep41565. PubMed PMID: 28134282; PubMed Central PMCID: PMC5278507.
AÑO: 2017; IF: 4.122
|
|
Orenes-Piñero E, Valdés M, Lip GY, Marín F. A comprehensive insight of novel antioxidant therapies for atrial fibrillation management. Drug Metab Rev. 2015 Aug;47(3):388-400. doi: 10.3109/03602532.2015.1077858. PubMed PMID: 27412960.
AÑO: 2015; IF: 4.526
|
|
Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, Marín F. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017 Jun 27;117(7):1448-1454. doi: 10.1160/TH16-12-0961. Epub 2017 Mar 23. PubMed PMID: 28331926.
AÑO: 2017; IF: 6.681
|
|
Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, Raña-Míguez P, Anguita M, Muñiz J, Cequier Á, Bertomeu-Martínez V, Valdés M, Vicente V, Lip GYH, Roldán V. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. Am J Cardiol. 2017 Dec 15;120(12):2176-2181. doi: 10.1016/j.amjcard.2017.09.003. Epub 2017 Sep 19. PubMed PMID: 29111209.
AÑO: 2017; IF: 3.171
|